首頁 > 市場調查報告書 > 製藥

藥物開發

In Silico藥物發現市場規模、佔有率和成長分析（按產品、工作流程、治療領域、最終用戶和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898404

In Silico藥物發現市場規模、佔有率和成長分析（按產品、工作流程、治療領域、最終用戶和地區分類）—產業預測（2026-2033 年）

Insilico Drug Discovery Market Size, Share, and Growth Analysis, By Product (Software-as-a-Service, Software), By Workflow (Pre-Clinical Tests, Discovery), By Target Therapeutic Area, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球In Silico藥物發現市場規模為 32.2 億美元，預計從 2025 年的 35.7 億美元成長到 2033 年的 82.4 億美元，在預測期（2026-2033 年）內複合年成長率為 11%。

由於生物資訊技術的進步，全球In Silico藥物發現市場正經歷顯著擴張。這些技術能夠促進藥物標靶辨識、候選分子開發和結合特性最佳化。藥物發現數據的快速成長，以及對生物標記識別和降低醫院再入院率及醫療差錯的日益重視，是推動市場成長的關鍵因素。此外，藥物發現領域計算方法的快速發展也進一步刺激了市場需求。In Silico藥物設計服務的成本效益和日益成長的接受度也對市場趨勢產生了積極影響。然而，價格壓力、外包以及開放原始碼軟體的威脅等挑戰可能會在短期內抑制這一成長勢頭。

推動全球In Silico藥物發現市場發展的因素

全球In Silico藥物發現市場的成長主要得益於生物標記識別技術的進步，這些技術增強了標靶治療的開發能力。此外，降低醫院再入院率和減少醫療錯誤的日益重視也推動了對更有效率藥物發現流程的需求。計算生物學領域計算技術的創新正在促進該領域的進一步發展。此外，In Silico藥物發現技術的改進也顯著促進了市場擴張，因為它能夠更快、更準確地識別潛在候選藥物，從而簡化整個藥物開發流程。這些因素共同為市場的持續成長奠定了堅實的基礎。

全球In Silico藥物發現市場面臨的限制因素

全球In Silico藥物發現市場面臨一個重大限制：此技術固有的分析時間窗口極短。這些分析間隔從幾納秒到幾百納秒不等，具體取決於模擬系統的大小和複雜性以及可用的計算資源。如此短的時間窗口往往會阻礙對蛋白質折疊動力學的準確動態，並導致蛋白質構象採樣不足。因此，有限的時間解析度給產生可靠且全面的資訊帶來了挑戰，而這些資訊對於有效的藥物發現過程至關重要。

全球In Silico藥物發現市場趨勢

全球In Silico藥物發現市場呈現出顯著趨勢，這主要得益於雲端工具的日益普及，它徹底改變了藥物研究人員進行藥物發現和開發的方式。雲端運算提供的柔軟性和可擴展性使研究人員能夠動態調整運算資源，從而加速資料分析和模型模擬。這種適應性使機構能夠根據特定計劃需求量身定做解決方案，提高藥物開發平臺各個階段的效率。此外，像BT的雲端運算生命科學平台這樣的平台提供客製化的製藥應用，簡化了從藥物發現到商業化的流程，並支援不同團隊之間的兼容性，而無需使用統一的應用程式。

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- Atomwise（美國）
- Insilico Medicine（香港）
- 伊克托斯（法國）
- 搖籃（美國）
- BenevolentAI（英國）
- 薛丁格（美國）
- Cloud Pharmaceuticals（美國）
- 數位（美國）
- 晶鐵（中國）
- BenevolentAI（英國）
- Biovista（美國）
- Certara（美國）
- Cloud Pharmaceuticals（美國）
- 晶鐵（中國）
- Atomwise（美國）
- Exscientia（英國）
- Insilico Medicine（香港）
- 伊克托斯（法國）
- 搖籃（美國）

結論與建議

簡介目錄

Product Code: SQMIG35J2032

Global Insilico Drug Discovery Market size was valued at USD 3.22 Billion in 2024 and is poised to grow from USD 3.57 Billion in 2025 to USD 8.24 Billion by 2033, growing at a CAGR of 11% during the forecast period (2026-2033).

The global in-silico drug discovery market is witnessing significant expansion driven by advancements in bioinformatics technologies, which facilitate the identification of drug targets, development of candidate molecules, and optimization of binding properties. The surge in drug discovery data is a primary catalyst for market growth, alongside the increasing emphasis on biomarker identification and efforts to minimize readmission rates and medical errors. Additionally, rapid enhancements in computational methodologies within drug discovery are further propelling market demand. The cost-effectiveness and growing acceptance of in-silico drug design services also contribute positively to market trends. However, challenges such as pricing pressures, outsourcing, and the threat posed by open-source software could moderate this growth trajectory in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insilico Drug Discovery Market Segments Analysis

Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insilico Drug Discovery Market

The growth of the global in-silico drug discovery market is largely driven by advancements in biomarker identification, which enhance the ability to develop targeted therapies. Additionally, the emphasis on reducing readmission rates and minimizing medical errors is propelling demand for more efficient drug discovery processes. Innovations in computational technology within the realm of computational biology are further accelerating progress. Furthermore, enhancements in in-silico drug discovery techniques contribute significantly to the market's expansion, enabling faster and more accurate identification of potential drug candidates while streamlining the overall drug development process. Together, these factors create a robust foundation for the market's continued growth.

Restraints in the Global Insilico Drug Discovery Market

The Global In-Silico Drug Discovery market faces a significant limitation due to the inherently short duration of analysis periods associated with this technology. These analysis intervals can vary from a few nanoseconds to several hundred nanoseconds, contingent upon the size and complexity of the simulated systems as well as the computational resources available. This brevity often hampers the ability to accurately predict protein folding dynamics, leading to insufficient sampling of protein conformations. Consequently, the limitations in temporal resolution pose challenges in generating reliable and comprehensive insights necessary for effective drug discovery processes.

Market Trends of the Global Insilico Drug Discovery Market

The Global In-Silico Drug Discovery market is witnessing a significant trend driven by the rising adoption of cloud-based tools, revolutionizing how pharmaceutical researchers approach drug development. The flexibility and scalability afforded by cloud computing enable researchers to adjust their computing resources dynamically, facilitating accelerated data analysis and model simulations. This adaptability allows organizations to tailor solutions to meet specific project needs, enhancing efficiency across various stages of the drug development pipeline. Furthermore, platforms like BT's Cloud Compute life sciences offer tailored pharmaceutical applications that streamline processes from discovery to commercialization, supporting compatibility across diverse teams without necessitating uniform application usage.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Insilico Drug Discovery Market Size by Product & CAGR (2026-2033)

Market Overview
Software-as-a-Service
Software
Consultancy-as-a-Service

Global Insilico Drug Discovery Market Size by Workflow & CAGR (2026-2033)

Market Overview
Pre-Clinical Tests
Discovery
Clinical Tests

Global Insilico Drug Discovery Market Size by Target Therapeutic Area & CAGR (2026-2033)

Market Overview
Metabolic disorders
HIV
Infectious diseases
Musculoskeletal disorders
Mental disorders
Neurological disorders
Oncological disorders

Global Insilico Drug Discovery Market Size by End User & CAGR (2026-2033)

Market Overview
Contract Research Organizations
Pharmaceutical and Biopharmaceutical Companies
Academic and Research Institutes
Others

Global Insilico Drug Discovery Market Size & CAGR (2026-2033)

North America (Product, Workflow, Target Therapeutic Area, End User)
- US
- Canada
Europe (Product, Workflow, Target Therapeutic Area, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Workflow, Target Therapeutic Area, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Workflow, Target Therapeutic Area, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Workflow, Target Therapeutic Area, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Atomwise (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Medicine (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iktos (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cradle (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BenevolentAI (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schrodinger (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cloud Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Numerate (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
XtalPi (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BenevolentAI (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biovista (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Certara (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cloud Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
XtalPi (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atomwise (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exscientia (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insilico Medicine (Hong Kong)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iktos (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cradle (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments